Zobrazeno 1 - 10
of 166
pro vyhledávání: '"V Upreti"'
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 19, Iss 6, Pp 841-843 (2015)
Endocrinology is a relatively newer field in medicine but it has gained tremendous progress in the recent past and is currently one of the most cherished and sought after superspecialty subject. The journey is long and an average of 12 years is spent
Externí odkaz:
https://doaj.org/article/90807051c38245beab6545bdc74e7e68
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 2, Pp 250-260 (2023)
Abstract Talimogene Laherparepvec (T‐VEC) is a first‐in‐class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery. Biodistribution data from a phase II study was used to develop a viral kine
Externí odkaz:
https://doaj.org/article/d1b7ce925d2e4b18b4554c4442799b30
Autor:
Tong-yuan Yang, Manuela Braun, Wibke Lembke, Fraser McBlane, John Kamerud, Stephen DeWall, Edit Tarcsa, Xiaodong Fang, Lena Hofer, Uma Kavita, Vijay V. Upreti, Swati Gupta, LiNa Loo, Alison J. Johnson, Rakesh Kantilal Chandode, Kay-Gunnar Stubenrauch, Maya Vinzing, Cindy Q. Xia, Vibha Jawa
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 26, Iss , Pp 471-494 (2022)
Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-associated virus (AAV) vector-based gene therapies. Mild to severe adverse events observed in clinical development have been implicated with host immune responses again
Externí odkaz:
https://doaj.org/article/1b85bb2274f44631a3d3b829f5704b0f
Autor:
Johannes Kast, Saeideh Nozohouri, Di Zhou, Marc R. Yago, Po‐Wei Chen, Malidi Ahamadi, Sandeep Dutta, Vijay V. Upreti
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 9, Pp 2057-2074 (2022)
Abstract Advances in immuno‐oncology have provided a variety of novel therapeutics that harness the innate immune system to identify and destroy neoplastic cells. It is noteworthy that acceptable safety profiles accompany the development of these t
Externí odkaz:
https://doaj.org/article/8506c62661e546e89357bc447bb8e20a
Autor:
Marc R. Yago, Khamir Mehta, Maitreyee Bose, Sharvari Bhagwat, Vivek S. Chopra, Sandeep Dutta, Vijay V. Upreti
Publikováno v:
Clinical Pharmacokinetics. 62:779-788
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a3b77a266089f56d4cd1f1e22c6ba5e
https://doi.org/10.1007/s40262-023-01242-6
https://doi.org/10.1007/s40262-023-01242-6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stergios J. Moschos, Shahneen Sandhu, Karl D. Lewis, Ryan J. Sullivan, Igor Puzanov, Douglas B. Johnson, Haby A. Henary, Hansen Wong, Vijay V. Upreti, Georgina V. Long, Keith T. Flaherty
Publikováno v:
Investigational New Drugs. 40:1051-1065
Background Targeting the MDM2-p53 interaction using AMG 232 is synergistic with MAPK inhibitors (MAPKi) in preclinical melanoma models. We postulated that AMG 232 plus MAPKi is safe and more effective than MAPKi alone in TP53-wild type, MAPKi-naïve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c5a9d4435c509fa8da92fc8a62a3144
https://doi.org/10.1007/s10637-022-01253-3
https://doi.org/10.1007/s10637-022-01253-3
Publikováno v:
CPT: pharmacometricssystems pharmacology.
Talimogene Laherparepvec (T-VEC) is a first in class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery. Biodistribution data from phase 2 study was used to develop a viral kinetics mechanistic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2dbe55e931bb5eb3dd76800963e21c2
https://pubmed.ncbi.nlm.nih.gov/36564918
https://pubmed.ncbi.nlm.nih.gov/36564918
Publikováno v:
Cancer chemotherapy and pharmacology
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Panitumumab is a human monoclonal antibody targeting the epidermal growth factor receptor for the treatment of wild-type RAS metastatic colorectal cancer (mCRC). Currently, no dedicated clinical studies have evaluated the effect of organ impa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::defb5da6ff97186340a10216fc0d2018
https://doi.org/10.1007/s00280-021-04319-w
https://doi.org/10.1007/s00280-021-04319-w
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.